Fundraising Fox
KDx Diagnostics
Campbell, US · Founded 2016 · Delaware corporation
Find your way into KDx Diagnostics
543 people in our graph share verified history with the KDx Diagnostics team — schools, employers, funds. One of them is your warm intro.
Ruth Segallunlockedknows Shahram Shawn Gholami · together at Arthrex (overlapped)
×2knows the team · via El Camino Health
×2knows the team · via Intuitive Surgical
×5knows the team · via UCSF
knows the team · via Stanford Hospitals & Clinics
knows the team · via Geron
KDx Diagnostics develops diagnostic tests for early detection and management of cancer, including the URO17 non-invasive urine test for bladder cancer based on the Keratin 17 biomarker. The URO17 test is offered in the US as a Laboratory Developed Test through reference laboratories and as a CE-IVD kit outside the US.
Founders & leadership
KDx Diagnostics was founded in 2016 by Shahram Shawn Gholami.
SS
Shahram Shawn GholamiCofounder and CMOHe holds an MD from Boston University and a BA in biological sciences from Cornell University, with fellowship training in surgical oncology at the Institute Mutualiste Montsouris in Paris and residency training in urology and general surgery at UCSF.
NK
Nam KimChief Executive Officer & Chief Technology OfficerNam Kim is an R&D scientist and biotech executive with over 30 years of experience in pharmaceuticals and biotechnology, with expertise in biomarker discovery, molecular diagnostics, and translational medicine across oncology and other therapeutic areas.
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 4 rounds · 2017–2019
▶$820KraisedMay 2019 · 16 investors · BiotechnologyRule 506(b)
▶$820KraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $820K
- Minimum investment
- $10K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$300KraisedMar 2019 · 2 investors · BiotechnologyRule 506(b)
▶$300KraisedMar 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $300K
- Minimum investment
- $100K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$100KraisedAug 2018 · 2 investors · BiotechnologyRule 506(b)
▶$100KraisedAug 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $100K
- Minimum investment
- $20K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$440KraisedDec 2017 · 6 investors · BiotechnologyRule 506(b)
▶$440KraisedDec 2017 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sholeh JahanfardExecutive Officer, Director
- Nam KimExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $440K
- Minimum investment
- $20K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAmerican Cancer Society (ACS)26 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Cancerresearchuk22 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer Center21 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Fred Hutch14 shared keywordsFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Companies competing with KDx Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does KDx Diagnostics do?
- KDx Diagnostics develops diagnostic tests for early detection and management of cancer, including the URO17 non-invasive urine test for bladder cancer based on the Keratin 17 biomarker. The URO17 test is offered in the US as a Laboratory Developed Test through reference laboratories and as a CE-IVD kit outside the US.
- Who founded KDx Diagnostics?
- KDx Diagnostics was founded by Shahram Shawn Gholami in 2016.
- How much funding has KDx Diagnostics raised?
- KDx Diagnostics has disclosed $1.7M raised across 4 rounds.
- Where is KDx Diagnostics headquartered?
- KDx Diagnostics is headquartered in Campbell, US.